PROFILPELAJAR.COM

Donitriptan
Clinical data
ATC code	None;
Legal status
Legal status	Never marketed;
Identifiers
	IUPAC name 4-[4-({[3-(2-Aminoethyl)-1H-indol-5-yl]oxy}acetyl)-1-piperazinyl]benzonitrile;
CAS Number	170912-52-4;
PubChem CID	197706;
ChemSpider	171128;
UNII	70968BVH2J;
ChEMBL	ChEMBL1742428;
CompTox Dashboard (EPA)	DTXSID20168974 ;
Chemical and physical data
Formula	C23H25N5O2
Molar mass	403.486 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc(ccc1C#N)N2CCN(CC2)C(=O)COc3ccc4c(c3)c(c[nH]4)CCN;
	InChI InChI=1S/C23H25N5O2/c24-8-7-18-15-26-22-6-5-20(13-21(18)22)30-16-23(29)28-11-9-27(10-12-28)19-3-1-17(14-25)2-4-19/h1-6,13,15,26H,7-12,16,24H2; Key:SOHCKWZVTCTQBG-UHFFFAOYSA-N;

Donitriptan (INN) (code name F-11356) is a triptan drug which was investigated as an antimigraine agent but ultimately was never marketed.^[1] It acts as a high-affinity, high-efficacy/near-full agonist of the 5-HT_1B (pK_i = 9.4–10.1; IA = 94%) and 5-HT_1D receptors (pK_i = 9.3–10.2; IA = 97%), and is among the most potent of the triptan series of drugs.^[2]^[3]^[4] Donitriptan was being developed in France by bioMérieux-Pierre Fabre and made it to phase II clinical trials in Europe before development was discontinued.^[5]^[6]^[7]

References

^ Dukat M (March 2001). "Donitriptan (Pierre Fabre)". Current Opinion in Investigational Drugs. 2 (3): 415–418. PMID 11575714.
^ Perez M, Fourrier C, Sigogneau I, Pauwels PJ, Palmier C, John GW, et al. (September 1995). "Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors". Journal of Medicinal Chemistry. 38 (18): 3602–3607. doi:10.1021/jm00018a020. PMID 7658447.
^ Saxena PR, Tfelt-Hansen P (2006). "Triptans, 5-HT1B/1D Receptor Agonists in the Acute Treatment of Migraine". In Olesen J (ed.). The Headaches. Lippincott Williams & Wilkins. pp. 470–. ISBN 978-0-7817-5400-2.
^ John GW, Pauwels PJ, Perez M, Halazy S, Le Grand B, Verscheure Y, et al. (July 1999). "F 11356, a novel 5-hydroxytryptamine (5-HT) derivative with potent, selective, and unique high intrinsic activity at 5-HT1B/1D receptors in models relevant to migraine". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 83–95. doi:10.1016/S0022-3565(24)34871-2. PMID 10381763.
^ Schmidt WK (28 May 2013). "An Overview of Current and Investigational Drugs for the Treatment of Acute and Chronic Pain". In Bountra C, Munglani R, Schmidt WK (eds.). Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery. CRC Press. pp. 402–. ISBN 978-0-203-91125-9.
^ Fleischhacker WW, Brooks DJ (21 May 2003). Neuropsychopharmacology. Springer Vienna. pp. 38–. ISBN 978-3-211-83903-4.
^ Tepper SJ (2004). "New Areas of Research". Understanding Migraine and Other Headaches. Univ. Press of Mississippi. pp. 118. ISBN 978-1-60473-048-7.